HSD17B13 (NM_178135) Human Recombinant Protein
SKU
TP313132
Recombinant protein of human hydroxysteroid (17-beta) dehydrogenase 13 (HSD17B13), transcript variant A, 20 µg
$867.00
In Stock*
Specifications
| Product Data | |
| Species | Human |
|---|---|
| Expression Host | HEK293 |
| Expression cDNA Clone or AA Sequence | |
| Tag | C-Myc/DDK |
| Predicted MW | 33.5 kDa |
| Concentration | >0.1 µg/µL as determined by microplate BCA method |
| Purity | > 80% as determined by SDS-PAGE and Coomassie blue staining |
| Buffer | 25 mM Tris-HCl, 100 mM glycine, pH 7.3, 10% glycerol |
| Preparation | Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. |
| Note | For testing in cell culture applications, please filter before use. Note that you may experience some loss of protein during the filtration process. |
| Storage | Store at -80°C. |
| Stability | Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. |
| Shipping | Dry Ice |
| Reference Data | |
| RefSeq | NP_835236 |
| Locus ID | 345275 |
| UniProt ID | Q7Z5P4 |
| Cytogenetics | 4q22.1 |
| RefSeq Size | 2397 |
| RefSeq ORF | 900 |
| Synonyms | HMFN0376; NIIL497; SCDR9; SDR16C3 |
| Protein Categories | Intracellular Proteins |
| Protein Families | Druggable Genome, Secreted Protein, Transmembrane |
Reviews
Documents
| FAQs |
| SDS |
Resources
| Recombinant Protein Resources |
Other "HSD17B13" proteins (9)
| SKU | Description | Size | Price | |
|---|---|---|---|---|
| PH313132 | HSD17B13 MS Standard C13 and N15-labeled recombinant protein (NP_835236) | 10 ug |
$3,360.00
|
|
| LC405941 | Lyophilized HSD17B13 HEK293T cell transient overexpression lysate (as WB positive control) | 20 ug |
$206.00
|
|
| LC427863 | Lyophilized HSD17B13 HEK293T cell transient overexpression lysate (as WB positive control) | 20 ug |
$206.00
|
|
| LC440268 | Lyophilized HSD17B13, transcript variant D, HEK 293T cell transient overexpression lysate (as WB positive control) | 20 ug |
$206.00
|
|
| LC440269 | Lyophilized HSD17B13, transcript variant C, HEK 293T cell transient overexpression lysate (as WB positive control) | 20 ug |
$206.00
|
|
| LY405941 | Transient overexpression lysate of hydroxysteroid (17-beta) dehydrogenase 13 (HSD17B13), transcript variant A (as WB positive control) | 100 ug |
$436.00
|
|
| LY427863 | Transient overexpression lysate of hydroxysteroid (17-beta) dehydrogenase 13 (HSD17B13), transcript variant B (as WB positive control) | 100 ug |
$436.00
|
|
| LY440268 | Transient overexpression lysate of human hydroxysteroid (17-beta) dehydrogenase 13 (HSD17B13), transcript variant D (as WB positive control) | 100 ug |
$436.00
|
|
| LY440269 | Transient overexpression lysate of human hydroxysteroid (17-beta) dehydrogenase 13 (HSD17B13), transcript variant C (as WB positive control) | 100 ug |
$436.00
|
|
Citations
Discovery of the First-In-Class HSD17B13/PPAR Multitarget Modulators for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Liang, Chen, Liao et al
J Med Chem (2025) 68 (21), 22938-22958 DOI: 10.1021/acs.jmedchem.5c01825
Liang, Chen, Liao et al
J Med Chem (2025) 68 (21), 22938-22958 DOI: 10.1021/acs.jmedchem.5c01825
Cited by 3
AI Summary: OriGene’s recombinant human and mouse HSD17B13 proteins (TP313132) were used to assess compound activity in enzyme inhibition assays, enabling the evaluation of multitarget modulators for treating metabolic dysfunction-associated steatohepatitis in this study.
Snippet: ds was assessed by NAD(P)H-Glo luciferase assay (Promega, G9061) using a purified recombinant human/mouse HSD17B13 protein (Origene, TP313132). … The mixture included 0.4 μL of compounds (50× FAC, 10% DMSO) and 2 μL/well of hHSD17B13 (65 nM FAC in assay buffer) or mHSD17B13 protein (120 nM FAC in assay buffer), which were added to a 384-well plate (Corning, 3872), and replicate points were designed at each concen
Discovery of Highly Potent, Selective, and Liver-Targeting HSD17B13 Inhibitor with Robust In Vivo Anti-MASH Activity
Chen, Liang, Mao et al
J Med Chem (2025)
Chen, Liang, Mao et al
J Med Chem (2025)
Cited by 10
Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science
Thamm, Willwacher, Aspnes et al
J Med Chem (2023) 66 (4), 2832-2850 DOI: 10.1021/acs.jmedchem.2c01884
Thamm, Willwacher, Aspnes et al
J Med Chem (2023) 66 (4), 2832-2850 DOI: 10.1021/acs.jmedchem.2c01884
Cited by 22
AI Summary: OriGene’s recombinant human HSD17B13 protein (cat# TP313132) was used in high-throughput screening and biochemical assays to identify and characterize the novel HSD17B13 inhibitor BI-3231 in this study.
Snippet: (1% DMSO final concentration in the assay). Experiments to select the high-throughput screening substrate were performed using commercially available recombinant human HSD17B13 (transcript variant A, OriGene cat# TP313132;final conc. 228 nM). Compound profiling and mode of inhibition studies were performed using purified, recombinant human HSD17B13 (final conc. 1 nM), human HSD17B11 (final conc
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆
Anstee, Darlay, Cockell et al
J. Hepatol. (2020) 73 (3), 505-515 DOI: 10.1016/j.jhep.2020.04.003
Anstee, Darlay, Cockell et al
J. Hepatol. (2020) 73 (3), 505-515 DOI: 10.1016/j.jhep.2020.04.003
Cited by 530
Showing 1-4 of 4 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen
complexities in the preparation of your product. International customers may expect an additional 1-2 weeks
in shipping.
Related Products
- Price:
- Actual Price:
Welcome to OriGene AI!
I'm your AI-powered guide to everything OriGene.
Ask me anything:
- Product specs
- Ordering help
- Technical questions
- How to find exactly what your experiment needs
Prefer a live agent? Connect with us by clicking the green chat icon, as seen in the image below or email our team at custsupport@origene.com.
